Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Apr 14, 2008

Kamada : Phase III Clinical Trial with Intravenous AAT

April 02, 2008 - Kamada, a biopharmaceutical company developing, producing and marketing a line of specialty, life-saving therapeutics, announced that it has successfully met the primary endpoint in the Phase III US clinical trials with its intravenous Alpha-1 Antitrypsin (AAT). The product is used to treat hereditary AAT deficiency which leads to Congenital Emphysema... Kamada's Press Release -